TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Dry powder and solvent for solution for infusion 15mg, 90mg (specialist use only)
Bisphosphonates used in malignant disease (Formulary)
Refer to Prevention of skeletal related events in cancer patients and guidance on hypercalcaemia in Scottish Palliative Care Guidelines.
Important: Therapy notes
MHRA advice: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation (June 2018) (www.gov.uk).
MHRA advice: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (June 2017) (www.gov.uk).
MHRA advice: Denosumab (Xgeva, Prolia): intravenous bisphosphonates: osteonecrosis of the jaw - further measures to minimise risk (July 2015) (www.gov.uk).
Important: Formulation and dosage details
Formulation:
Solution for injection (Xgeva®) 120mg/1·7mL (specialist use only)
Dosage:
See SMC advice 651/10.
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Tablets 50mg, 150mg (specialist use only)
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Tablets 800mg (specialist use only)
Important: Therapy notes
For reduction of bone damage in advanced malignancies involving bone and hypercalcaemia of malignancy.
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Solution for infusion 4mg/5mL (specialist use only)